 |
 |
|
|
|
| Ambrisentan |
 |
| (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid |
 |
| 177036-94-1 |
 |
| Ambrisentan ) is an orally-active endothelin-A receptor antagonist, developed by Abbott for the treatment of pulmonary arterial hypertension (PAH), chronic heart failure and chronic renal failure. |
 |
Description: Yellowish to white crystalline powder
Loss on drying NMT 1.0%
Residue on ignition NMT 0.2%
Related substances NMT 1.0% (HPLC)
Assay: 98.0--102.0% (HPLC) |
|
|
|
|
|
